Schedule-dependent effects of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus (RAD001)

被引：0

作者：

Di Cosimo, S

Matar, P

Rojo, F

Guzman, M

Rodriguez, S

Jimenez, J

Arribas, J

Cognetti, F

Lane, H

Baselga, J

机构：

[1] Vall Hebron Univ Hosp, Barcelona, Spain

[2] Regina Elena Inst Canc Res, I-00161 Rome, Italy

[3] Novartis Pharma AG, Basel, Switzerland

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3074

引用

页码：213S / 213S

页数：1

共 50 条

[31] Combination therapy of inhibitors of the epidermal growth factor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.
Goudar, R
Keir, S
Hjelmeland, M
Conrad, C
Traxler, P
Lane, H
Wang, XF
Bigner, DD
Friedman, HS
Rich, JN
CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6090S - 6090S
[32] The mammalian target of rapamycin inhibitor RAD001 (everolimus) in postmenopausal women with early breast cancer: results of a phase II pre-operative trial.
Macaskill, E. J.
Bartlett, J. M. S.
White, S.
Renshaw, L.
Campbell, F. M.
Young, O.
Stumm, M.
Faratian, D.
Thomas, J. S.
Barber, M. D.
Dixon, J. M.
BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S286 - S287
[33] The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia
Saunders, Philip
Cisterne, Adam
Weiss, Jocelyn
Bradstock, Kenneth F.
Bendall, Linda J.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (01): : 69 - 77
[34] Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non-small cell lung cancer
Johnson, Bruce E.
Jackman, David
Janne, Pasi A.
CLINICAL CANCER RESEARCH, 2007, 13 (15) : 4628S - 4631S
[35] Growth inhibition in head and neck cancer cell lines by gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor
Song, Seung-Il
Kim, Myung-Jin
JOURNAL OF THE KOREAN ASSOCIATION OF ORAL AND MAXILLOFACIAL SURGEONS, 2009, 35 (05) : 287 - 293
[36] Enhanced and schedule-dependent antitumour activity of the combination gefitinib (ZD1839; 'Iressa') and the mTor inhibitor rapamycin in a panel of pancreas cancer cell lines.
Porcelli, L
Azzariti, A
Sebastian, S
Simone, GM
Gatti, G
Nicolin, A
Paradiso, A
CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9044S - 9044S
[37] The mTOR inhibitor RAD001 (Everolimus) inhibits myeloma tumor growth in vivo and enhances the anti-MM effects of bortezomib and arsenic trioxide
Campbell, Richard A.
Sanchez, Eric
Steinberg, Jeffrey
Share, Michael
Wang, Joseph
Li, Mingjie
Leuchter, Richard
Chen, Hamoing
Shalitin, Dror
Pang, Shen
Said, Jonathan
Berenson, James R.
BLOOD, 2007, 110 (11) : 274B - 274B
[38] Phase I trial of the mTOR inhibitor RAD001 (R) in combination with two schedules of the vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor PTK787/ZK 222584 (P) in patients (pts) with advanced solid tumors
Dy, G. K.
Croghan, G. A.
Qi, Y.
Glockner, J.
Hanson, L.
Roos, M.
Tan, A. D.
Molina, J. R.
Adjei, A. A.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[39] A phase II study of mammalian target of rapamycin (mTOR) inhibitor RAD001 plus imatinib mesylate (IM) in patients with previously treated advanced renal carcinoma (RCC)
Chan, J. S.
Vuky, J.
Besaw, L. A.
Beer, T. M.
Ryan, C. W.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[40] Timing of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer With EGFR Mutations
Moran, Teresa
Sequist, Lecia V.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27) : 3330 - 3336

← 1 2 3 4 5 →